COVID-19 in kidney transplant recipients
| Autor: | Gayatri Nair, Andrew J. Dominello, David Hirschwerk, Ernesto P. Molmenti, Madhu Bhaskaran, Safiya Richardson, Elliot Grodstein, Gabrielle A. Osorio, Stuart L. Cohen, Karina W. Davidson, Jamie S. Hirsch, Ilan Berlinrut, Lewis W. Teperman, Mersema Abate, Vinay Nair, Nicholas Jandovitz |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
myalgia medicine.medical_specialty Critical Care medicine.medical_treatment Pneumonia Viral New York kidney transplantation/nephrology kidney (allograft) function/dysfunction clinical research/practice Betacoronavirus Immunocompromised Host COVID-19 Testing infection and infectious agents ‐ viral Interquartile range Prednisone Internal medicine medicine Electronic Health Records Humans Immunology and Allergy Pharmacology (medical) Pandemics Kidney transplantation Aged Immunosuppression Therapy Transplantation Clinical Laboratory Techniques SARS-CoV-2 business.industry Acute kidney injury COVID-19 Immunosuppression Original Articles Middle Aged medicine.disease Kidney Transplantation Transplant Recipients Tacrolimus Hospitalization Kidney Failure Chronic Female Original Article Chills medicine.symptom Coronavirus Infections business medicine.drug |
| Zdroj: | American Journal of Transplantation |
| ISSN: | 1600-6135 |
| Popis: | There is minimal information on coronavirus disease 2019 (COVID‐19) in immunocompromised individuals. We have studied 10 patients treated at 12 adult care hospitals. Ten kidney transplant recipients tested positive for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) by polymerase chain reaction, and 9 were admitted. The median age was 57 (interquartile range [IQR] 47‐67), 60% were male, 40% Caucasian, and 30% Black/African American. Median time from transplant to COVID‐19 testing was 2822 days (IQR 1272‐4592). The most common symptom was fever, followed by cough, myalgia, chills, and fatigue. The most common chest X‐ray and computed tomography abnormality was multifocal patchy opacities. Three patients had no abnormal findings. Leukopenia was seen in 20% of patients, and allograft function was stable in 50% of patients. Nine patients were on tacrolimus and a mycophenolic antimetabolite, and 70% were on prednisone. Hospitalized patients had their antimetabolite agent stopped. All hospitalized patients received hydroxychloroquine and azithromycin. Three patients died (30%), and 5 (50%) developed acute kidney injury. Kidney transplant recipients infected with COVID‐19 should be monitored closely in the setting of lowered immunosuppression. Most individuals required hospitalization and presenting symptoms were similar to those of nontransplant individuals. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text